OBJECTIVE: We describe @entity2590 ( @entity2590 )-associated @entity792 ( @entity792 ), their treatments and outcomes and the impact of @entity792 on overall survival in a French multicentre retrospective study. METHODS: In this study, 123 @entity1 with @entity2590 and @entity792 were analysed. RESULTS: Mean age was 70 years (s.d. 13) and the male:female ratio was 2. The @entity792 were systemic @entity1333 in 39 (32%) cases, CTD in 31 (25%) cases, @entity625 in 28 (23%) cases, a @entity74 in 12 (10%) cases and unclassified in 13 cases (11%). The @entity792 fulfilled the usual classification criteria in 75 (66%) cases, while complete criteria were not reached in 21 (19%) cases. A significant association was shown between @entity6130 ( @entity6130 ) and systemic @entity1333 (P = 0.0024). One hundred and eighteen (96%) SIAD @entity1 were treated (91% with @entity230 ), with an 83% response to first-line treatment, including 80% for @entity230 alone. A second-line treatment for @entity792 was required for @entity479 dependence or relapse in 48% of cases. The effect of @entity2590 treatment on @entity792 could be assessed in 11 @entity1 treated with @entity2591 and SIAD response was achieved in 9/11 (80%) and 6/11 (55%) @entity1 at 3 and 6 months, respectively. Compared with 665 @entity2590 / @entity6130 @entity1 without @entity792 , @entity2590 / @entity6130 @entity1 with @entity792 were younger (P < 0.01), male (P = 0.03), less often had refractory anaemia with ring sideroblasts (P < 0.01), more often had a poor karyotype (16% vs 11%, P = 0.04) and less frequently belonged to low and intermediate-1 International Prognostic Scoring System categories, but no survival difference was seen between @entity1 with @entity2590 -associated @entity792 and without @entity792 (P = 0.5). CONCLUSION: The spectrum of @entity792 associated to @entity2590 is heterogeneous, @entity479 sensitive, but often @entity479 dependent.

Systemic inflammatory and autoimmune manifestations associated with XXXX and @entity6130 : a French multicentre retrospective study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2591 :: ('MESH:D001374', 'Chemical') :: ['azacytidine'] @entity625 :: ('MESH:D001168', 'Disease') :: ['inflammatory arthritis'] @entity1333 :: ('MESH:D014657', 'Disease') :: ['vasculitis'] @entity6130 :: ('MESH:D015477', 'Disease') :: ['CMML', 'chronic myelomonocytic leukaemia'] @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndrome', 'MDS'] @entity74 :: ('MESH:D030342', 'Disease') :: ['neutrophilic disorder'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity792 :: ('MESH:D001327', 'Disease') :: ['SIADs', 'systemic inflammatory and autoimmune diseases'] @entity479 :: ('D013256', 'Chemical') :: ['steroid']
@entity2590 :: (MESH:D009190,Disease) :: ['myelodysplastic syndromes']
